Your browser doesn't support javascript.
loading
Risk for graft loss in pediatric and young adult kidney transplant recipients due to recurrent IgA nephropathy.
Engen, Rachel M; Bartosh, Sharon M; Smith, Jodi M; Perkins, James D; Harshman, Lyndsay A.
Afiliação
  • Engen RM; University of Wisconsin Madison, Madison, Wisconsin, USA. Electronic address: rengen@wisc.edu.
  • Bartosh SM; University of Wisconsin Madison, Madison, Wisconsin, USA.
  • Smith JM; University of Washington, Seattle, Washington DC, USA.
  • Perkins JD; Clinical and Bio-Analytics Transplant Laboratory (CBATL), Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, Washington DC, USA.
  • Harshman LA; University of Iowa Organ Transplant Center, Iowa City, Iowa, USA.
Am J Transplant ; 24(1): 37-45, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37595842
ABSTRACT
IgA nephropathy (IgAN) is associated with a risk for posttransplant recurrence. Data are limited regarding graft loss attributable to recurrence of IgAN among pediatric and young adult kidney transplant (KT) recipients. This was a retrospective cohort study of patients aged 0 to 25 years from the Scientific Registry of Transplant Recipients who received a primary KT for IgAN. Patients with history of KT attributable to renal dysplasia were comparators. Outcomes included the incidence of graft loss attributable to IgAN recurrence, association with donor type, and posttransplant corticosteroid use. In total, 5475 transplant recipients were included, with 1915 patients with IgAN and 3560 patients with renal dysplasia. In a multivariable Cox proportional hazards model, IgAN was associated with higher risk of graft loss (adjusted hazard ratio [aHR], 1.35; 95% CI, 1.21-1.50; P < .001) compared with dysplasia. Graft loss was attributed to recurrent disease in 5.4% of patients with IgAN. In a multivariable competing risks analysis, patients with IgAN receiving a parental living-donor kidney were more likely to report graft loss from recurrent disease compared with patients with a nonparental living donor (aHR, 0.52; 95% CI, 0.31-0.91; P = .02). Posttransplant prednisone use was not associated with improved graft survival (P = .2). These data challenge existing paradigms in posttransplant management of patients with IgAN.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Glomerulonefrite por IGA Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Revista: Am J Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Glomerulonefrite por IGA Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Revista: Am J Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2024 Tipo de documento: Article